Genmab — September 2019
-
Bi´en stikker. Verdensklassehumor.
-
-
Sellebjerg: Flere RRMS-patienter vil starte direkte i højeffektiv behandling
CD20-antistoffet ofatumumab viser – helt som forventet – stærke resultater for både effekt og sikkerhed sammenlignet med Aubagio (teriflunomid) i fase III studierne ASCLEPIOS I og II.
(mstidsskrift.dk)
-
Det er altså ret kikset i den artikel. Jeg sender en mail til redaktionen , hvis ikke en af jer andre ikke allerede har gjort det.
-
Har sendt en sms til journalisten.
-
BartsMS har sin egen favorit (tjek også kommentarer) https://multiple-sclerosis-research.org/2019/09/open-letter-to-the-ema/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind